Medeon Biodesign (ROCO:6499) ROCE % : -38.53% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medeon Biodesign's annualized ROCE % for the quarter that ended in Jun. 2024 was -38.53%.

Medeon Biodesign ROCE % Historical Data

The historical data trend for Medeon Biodesign's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign ROCE % Chart

Medeon Biodesign Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

12.93

-12.13

-12.47

-14.01

-10.79

Medeon Biodesign Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-20.17	-73.51	-28.80	-33.32	-38.53

Medeon Biodesign ROCE % Calculation

Medeon Biodesign's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-433.904	/	( ( (4364.49 - 160.297)	+	(4040.023 - 198.514) )	/ 2 )
	=	-433.904	/	( (4204.193	+	3841.509)	/ 2 )
	=	-433.904	/	4022.851
	=	-10.79 %

Medeon Biodesign's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-858.42	/	( ( (2557.756 - 213.088)	+	(2299.417 - 187.758) )	/ 2 )
	=	-858.42	/	( ( 2344.668	+	2111.659 )	/ 2 )
	=	-858.42	/	2228.1635
	=	-38.53 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Medeon Biodesign (ROCO:6499) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medeon Biodesign ROCE % Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medeon Biodesign Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170

Website

http://www.medeonbio.com

Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign Headlines

No Headlines